


IN THE CLAIMS:

Claim 1 (currently amended): A compound of formula (I)



|

or a pharmaceutically acceptable salt and pharmaceutically acceptable salts and solvates thereof,
in which

R¹ represents

- a) a C₃₋₆alkoxy group substituted by one or more fluoro,
- b) a group of formula phenyl(CH₂)_pO- in which p is 1, 2 or 3 and the phenyl ring is optionally substituted by 1, 2 or 3 groups represented by Z,
- c) a group R⁶S(O)₂O or R⁶S(O)₂NH in which R⁶ represents a C₁₋₆alkyl group optionally substituted by one or more fluoro, or R⁶ represents phenyl or a heteroaryl group each of which is optionally substituted by 1, 2 or 3 groups represented by Z, or or
- d) a group of formula (R⁷)₃Si in which R⁷ represents a C₁₋₆alkyl group which may be the same or different;

R^a represents halo, a C₁₋₃alkyl group or a C₁₋₃alkoxy group, and m is 0, 1, 2 or 3;

R² represents a C₁₋₃alkyl group, a C₁₋₃alkoxy group, hydroxy, nitro, cyano or halo, and n is 0, 1, 2 or 3;

R³ represents H, a C₁₋₆alkyl group, a C₁₋₆alkoxy group or a C₁₋₆alkoxyC₁₋₆alkylene group which contains a maximum of 6 carbon atoms, each of which groups is optionally substituted by one or more fluoro or cyano;

R⁴ represents

a) a group $X-Y-NR^8R^9$ in which

X is CO or SO_{2-1}

Y is absent or represents NH optionally substituted by a C_{1-3} alkyl group; and

R^8 and R^9 independently represent:

a C_{1-6} alkyl group optionally substituted by 1, 2, or 3 groups represented by W;

a C_{3-15} cycloalkyl group optionally substituted by 1, 2, or 3 groups represented by W;

an optionally substituted $(C_{3-15}$ cycloalkyl) C_{1-3} alkylene group optionally substituted by 1, 2, or 3 groups represented by W;

a group $-(CH_2)_r(phenyl)_s$ in which r is 0,1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by one, two or three groups represented by Z;

a saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following : oxygen, sulphur or an additional nitrogen wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy or benzyl;

a group $-(CH_2)_tHET$ in which t is 0,1, 2, 3 or 4, and the alkylene chain is optionally substituted by one or more C_{1-3} alkyl groups and HET represents an aromatic heterocycle optionally substituted by one, two or three groups selected from a C_{1-5} alkyl group, a C_{1-5} alkoxy group or halo;

or R^8 represents H and R^9 is as defined above;

or R^8 and R^9 together with the nitrogen atom to which they are attached represent a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy, fluoro or benzyl; or


b) oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienyl, furyl or oxazolinyl, each optionally substituted by 1, 2 or 3 groups Z;

R^5 represents H or a C_{1-3} alkyl group;

Z represents a C₁₋₃alkyl group, a C₁₋₃alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di C₁₋₃alkylamino, C₁₋₃alkylsulphonyl, C₁₋₃alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C₁₋₃alkyl carbamoyl and acetyl; and

W represents hydroxy, fluoro, a C₁₋₃alkyl group, a C₁₋₃alkoxy group, amino, mono or di C₁₋₃alkylamino, or a heterocyclic amine selected from morpholinyl, pyrrolidinyl, piperdinyl or piperazinyl in which the heterocyclic amine is optionally substituted by a C₁₋₃alkyl group or hydroxyl.

Claim 2 (currently amended): A compound of formula (IA)



in which

R¹ is

- a) a C₃₋₆alkoxy group substituted by one or more fluoro,
- b) a group of formula phenyl(CH₂)_pO- in which p is 1, 2 or 3 and the phenyl ring is optionally substituted by 1, 2 or 3 groups represented by Z,
- c) a group R⁶S(O)₂O or R⁶S(O)₂NH in which R⁶ represents a C₁₋₆alkyl group optionally substituted by one or more fluoro, or R⁶ represents phenyl or a heteroaryl group each of which is optionally substituted by 1, 2 or 3 groups represented by Z, or
- d) a group of formula (R⁷)₃Si in which R⁷ represents a C₁₋₆alkyl group which may be the same or different;

R^{2a} represents chloro;

R^{2b} represents chloro;

R^3 represents a C_{1-3} alkyl group;

R^4 represents a group $CONHNR^8R^9$ in which NR^8R^9 represents piperidino; and

R^5 represents H.

Claim 3 (currently amended): A compound selected from ~~one or more of the following:~~

1-[4(benzyloxy)phenyl]-5-(2,4-dichlorophenyl)-2-methyl-N-piperidin-1-yl-1H-pyrrole-3-carboxamide;

4-{5-(2,4-dichlorophenyl)-2-methyl-3-[piperidin-1-ylamino]carbonyl}-1H-pyrrol-1-yl}phenyl trifluoromethanesulfonate;

5-(2,4-dichlorophenyl)-2-methyl-N-piperidin-1-yl-1-(4-(3,3,3-trifluoropropoxyphenyl))-1H-pyrrole-3-carboxamide;

4-{5-(2,4-dichlorophenyl)-2-methyl-3-[(piperidin-1-ylamino)carbonyl]-1H-pyrrol-1-yl}phenyl butane-1-sulfonate;

5-(2,4-Dichloro-phenyl)-2-methyl-1-(4-trimethylsilyl-phenyl)-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide; and

4-{5-(2,4-dichlorophenyl)-2-methyl-3-[(piperidin-1-ylamino)carbonyl]-1H-pyrrol-1-yl}phenyl propane-1-sulfonate;

as well as or a pharmaceutically acceptable salt salts thereof.

Claim 4 (cancelled).

Claim 5 (currently amended): A pharmaceutical composition-formulation comprising a compound of formula I or formula IA according to any one of claims 1 to 3 and a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 6 (cancelled).

Claim 7 (currently amended): A method of treating obesity, psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxi-depressive disorders,

depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, and related conditions, neurological disorders, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal system, and extended abuse, addiction and/or relapse indications in a warm blooded animal in need thereof, comprising administering to said animal a pharmacologically effective amount of a compound of formula I or formula IA according to any one of claims 1 to 3 ~~to a patient in need thereof~~.

Claim 8 (cancelled).

Claim 9 (**new**): A method of treating obesity in a warm blooded animal in need thereof, comprising administering to said animal a pharmacologically effective amount of a compound of formula I or formula IA according to any one of claims 1 to 3.